# An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

> **NCT04745988** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Center Hospital East** · enrollment: 43 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Lenvatinib 20mg
- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib 8mg
- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Levofolinate
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT04745988
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-11
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745988, "An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04745988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*